Previous Close | 44.43 |
Open | 44.52 |
Bid | 46.76 x 100 |
Ask | 46.83 x 200 |
Day's Range | 44.01 - 47.16 |
52 Week Range | 15.50 - 47.58 |
Volume | |
Avg. Volume | 760,226 |
Market Cap | 3.648B |
Beta (5Y Monthly) | 0.62 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Jeff Knight, the Chief Operating Officer of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), has sold 32,359 shares of the company on March 22, 2024, according to a recent SEC filing.
Chief Medical and Development Officer Dana Pizzuti of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) sold 15,089 shares of the company on March 20, 2024, according to a recent SEC filing.
Director Matthew Fust has sold 60,000 shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) on March 20, 2024, according to a recent SEC Filing.